首页> 外文期刊>Therapeutic advances in urology. >Opportunities for use of radiation therapy in penile cancer based on patterns of care in the United States from 2007 to 2013
【24h】

Opportunities for use of radiation therapy in penile cancer based on patterns of care in the United States from 2007 to 2013

机译:2007年至2013年在美国根据照护模式在阴茎癌中使用放射疗法的机会

获取原文
       

摘要

Radiation therapy (RT) is an effective modality for the treatment of squamous cell carcinomas of the penis. The National Comprehensive Cancer Network recommends consideration of primary radiation for penile preservation, in surgically unresectable tumors, and as adjuvant therapy for positive margins, bulky groin nodes or pelvic nodes. We performed a population-based analysis to evaluate the usage of RT in penile cancer from 2007 to 2013. We used the Surveillance, Epidemiology and End Results (SEER) database to identify men diagnosed with squamous cell carcinoma of the penis from 2007 to 2013. Patients were grouped as early stage (T1–T2N0), locally advanced (T3–T4N0), node-positive (T1xN1–3) and metastatic. We used linear regression model to test for factors associated with adjuvant radiation in node-positive patients. We identified 2200 men diagnosed with penile cancer between 2007 and 2013. Of these, 66.4% had early stage, 10.7% had locally advanced, 15.5% had node-positive, 3.2% had metastatic cancer. Among patient with early stage cancer, RT was used in 14 patients (1.0%) and postoperative radiation in an additional 45 patients (3.1%). Among 340 patients with node-positive cancer, 62.1% received surgery alone, 5.6% radiation alone, 21.8% surgery with adjuvant radiation, and 10.6% neither surgery nor radiation. Of patients who had surgery, 26.0% had adjuvant radiation. On univariate analysis, higher nodal stage (N2–3 versus N1) was associated with adjuvant radiation (p = 0.02), while there was a trend for higher T-stage (T3/T4 versus T1/T2) (p = 0.08) and history of prior malignancy (p = 0.06). On multivariate analysis, only higher nodal stage (N2–3 versus N1) was associated with use of adjuvant radiation [hazard ratio (HR) 1.94, p = 0.03]. A small percentage of patient who are eligible for primary or adjuvant RT in the United States receive this treatment. Further work should be done to assess barriers to use of radiation in patients with penile cancer.
机译:放射疗法(RT)是治疗阴茎鳞状细胞癌的有效方法。国家综合癌症网络建议考虑将主要放射线用于保留阴茎,手术切除的肿瘤以及作为阳性切缘,大腹股沟淋巴结或骨盆淋巴结的辅助治疗。我们进行了一项基于人群的分析,以评估2007年至2013年阴茎癌中RT的使用情况。我们使用监测,流行病学和最终结果(SEER)数据库来鉴定2007年至2013年诊断为阴茎鳞状细胞癌的男性。患者分为早期(T1-T2N0),局部晚期(T3-T4N0),淋巴结阳性(T1xN1-3)和转移性。我们使用线性回归模型来测试与淋巴结阳性患者的辅助放疗相关的因素。我们在2007年至2013年期间确定了2200名被诊断为阴茎癌的男性。其中,早期阶段为66.4%,局部晚期为10.7%,淋巴结阳性为15.5%,转移性癌症为3.2%。在早期癌症患者中,有14例患者(1.0%)使用了RT,另外45例患者(3.1%)使用了术后放疗。在340例淋巴结阳性患者中,仅接受手术的占62.1%,仅接受放射治疗的占5.6%,接受辅助放射治疗的占21.8%,未接受手术和不接受放射的占10.6%。在接受手术治疗的患者中,有26.0%接受了辅助放疗。在单因素分析中,较高的淋巴结分期(N2–3比N1)与辅助放疗相关(p = 0.02),而存在较高的T期分期(T3 / T4与T1 / T2)(p = 0.08)和既往恶性肿瘤病史(p = 0.06)。在多变量分析中,只有较高的淋巴结分期(N2–3比N1)与辅助放疗相关[危险比(HR)1.94,p = 0.03]。在美国,符合条件的原发性或辅助性RT患者中有一小部分接受这种治疗。应该做进一步的工作来评估阴茎癌患者使用放射线的障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号